Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

SL-401 shows preclinical activity in systemic sclerosis
August 2018
SHARING OPTIONS:

NEW YORK—This year’s Annual European Congress of Rheumatology in Amsterdam saw Stemline Therapeutics Inc. present preclinical data on the effects of Elzonris in systemic sclerosis (SSc). Elzonris showed activity against potentially pathogenic plasmacytoid dendritic cells (pDCs). pDCs, which play a role in inflammation and pathogenesis seen in some autoimmune diseases—including systemic sclerosis—secrete IFN-α and are immune to cells that express CD123. Elzonris is cytotoxic against CD123+ pDCs, and the reduction of IFN-α and IL-6 was seen in cell culture supernatant when pDCs were destroyed. As noted in a press release, “Depletion of pDCs or attenuation of pDC function may represent a novel mechanism of action for the treatment of patients with Ssc.” The data were presented in a poster titled “SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), Kills Plasmacytoid Dendritic Cells (pDCs) from Systemic Sclerosis Patients.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.